Table 4. Adjusted Multivariate Models Exploring the Association between BK Viremia and Subsequent Hemorrhagic Cystitis*.
| Variable | Peak BK Viremia 1 to 9999 copies/mL | Peak BK Viremia ≥ 100,000 copies/mL | ||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||
| Model 1 | Model 2 | Model 3 | Model 4 | Model 1 | Model 2 | Model 3 | Model 4 | |
| BK viremia | 5.2 (1.9 to 14.5) p<.01 | 4.8 (1.7 to 13.6) P <.01 | 6.4 (2.2 to 19.0) P<.01 | 4.2 (1.3 to 13.7) P = .02 | 41.4(5.1 to 336) P<.01 | 44.2 (5.6 to 346) P<.01 | 67.9 (7.1 to 651) P <.01 | 116.8 (12.0 to 1136) P <.01 |
| Age > 7 yr | 3.1 (1.0 to 9.4) P = .05 | 2.9 (.9 to 8.9) P = .06 | 3.8 (1.2 to 12.3) P = .02 | 7.7 (1.9 to 31.8) P <.01 | 3.5 (1.1 to 10.9) P = .03 | 3.9 (1.2 to 12.6) P = .02 | 3.5 (1.1 to 11.3) P = .04 | 9.2 (2.3 to 37.4) P <.01 |
| Antithymocyte globulin conditioning | - | 2.9(1.1 to 7.9) P = .04 | 33(1.2 to 9.2) P = .02 | 2.3 (.8 to 6.9) P = .13 | - | 3.3(1.2 to 9.0) P = .02 | 3.7 (1.3 to 10.5) P = .01 | 2.7 (.9 to 8.3) P = .09 |
| Platelet engraftment (> 50,000/μL) | - | - | .2(.05 to .9) P = .03 | .3 (.06 to 1.3) P = .ll | - | - | 0.2 (.04 to 1.2) P =.08 | 0.3 (.06 to 1.8) P = .21 |
| HHV-6 viremia | _ | _ | _ | 7.2 (1.8 to 29.8) P <.01 | _ | _ | _ | 16.9 (4.2 to 68.1) P <.01 |
Data presented as hazard ratios (95% confidence intervals). Bold typeface indicates statistical significance.
*
Adjusted for all variables listed. Busulfan, cyclophosphamide, type of conditioning (myeloablative versus reduced intensity), and posttransplantation thrombotic microangiopathy were not significant covariates when added to the models.